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Background: Disparities in the spectrum of mutations within the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene are
commonly observed in populations from different ethnical and/or geographical origins. The occurrence of CF in Brittany (western France) is
one of the highest in populations from Caucasian origin (b1/2000 in specific areas). The W846X2, 1078delT and G551D mutations, as well
as the I1027T polymorphism in cis with the ΔF508 mutation (currently referred to as p.F508del) are particularly frequent in this area. We
investigated the age of the respective variants in the region of interest.
Methods: Several polymorphic markers surrounding the CFTR gene were genotyped. Allele frequencies as well as mutation rates and other
parameters were used to calculate the respective age of the most recent common ancestors in the region of interest by a previously employed,
simple likelihood-based method.
Results: Following haplotype reconstruction and simulation, the ages were estimated to be approximately 600, 1000, 1200 and 600 years,
respectively (with a 95% confidence interval).
Conclusions: These datings thus provide historical insights in the context of understanding population migrations. They also underline the
usefulness of this method for estimating the age of rare mutations with a limited number of carriers.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; CFTR; Mutations; Datations; Haplotypes1. Introduction
Cystic fibrosis (CF; OMIM# 219700) is one of the most
common autosomal recessive disorder affecting children in
Caucasian populations, with an incidence of ∼1/3500 [1].
CF phenotype is characterized by inflammation and chronic☆ Data were presented at The American Society of Human Genetics 56th
Annual Meeting, New Orleans, Louisiana, USA, October 9–13, 2006.
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doi:10.1016/j.jcf.2007.07.009infections leading to alteration of pulmonary functions,
abnormal exocrine gland secretions, digestive troubles and
pancreatic insufficiency. The disease is caused by mutations
within the CF transmembrane conductance regulator (CFTR)
gene, which encodes a cAMP-dependent chloride channel
that is found at the apical membrane of epithelial cells [2–4].
Although more than 1500 mutations and sequence
variations have been reported to date (www.genet.sickkids.
on.ca/cftr), the ΔF508 mutation, which consists of the
deletion of a phenylalanine aminoacid at position 508 of the
protein, accounts for ∼70% of the total mutated alleles [2].
Only four additional mutations (i.e., G542X, G551D,ed by Elsevier B.V. All rights reserved.
Table 1
Genotypes of CF patients
W846X2 1078delT G551D
Mutation
in trans
Number Mutation
in trans
Number Mutation
in trans
Number
ΔF508 6 ΔF508 21 ΔF508 18
R117C 1 1078delTa 2 E60K 1
ΔI507 1 4005+1GNA 2 W79X 1
Y563N 1 L610S 1 C225X 1
1078delT b 1 W846X2
b 1 F311L 1
621+1GNT 1 R1066H 1 R347H 1
2789+5GNA 1 1221delCT 1 G542X 1
3849+4ANG 1 1717-1GNA 1 G551D 1
3659delC 1 R553G 1
S942F 1
Y1092X 1
621+1GNT 1
2789+5GNA 1
4006-1GNA 1
Unidentified 1
Total 13 Total 31 Total 32
a One particular case: in this individual, the two chromosomes 7 are
identical by descent. Only one chromosome has thus been taken into
consideration for the calculation.
b One family is involved in both the W846X2 and 1078delT mutation
studies.
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population [5]. However, disparities exist between popula-
tions from different ethnical and/or geographical origins.
We have been studying CFTR mutations that are
preferentially observed in Brittany, western France [6]:
G551D [7], 1078delT [8] and W846X2 [9] mutations, which
respective frequencies are 3.7%, 3.8% and 1.1% [10–12]. A
haplotype we have also been interested in is the ΔF508-
I1027T haplotype. It consists of the cis-association of the
ΔF508 mutation and the I1027T polymorphism. This
haplotype is typically found in the population of interest
with a frequency N5% of the ΔF508-carrying chromosomes
(Audrézet and Férec, unpublished data).
In this study, we intended to estimate the age of the most
recent common ancestors carrying the mutations and the
polymorphism described above in the population from
Brittany. This work significantly differ from previous
attempts for aging CFTR mutations in the whole population.
In separate reports, Serre et al. [13] estimated the age of the
ΔF508 mutation to be 3000–6000 years old while Morral et
al. [14,15] evaluated the number of generations to be N2100
(N52 000 years) by studying three intronic, intragenic
microsatellite markers (i.e. IVS8CA, IVS17bTA and
IVS17bCA). Likewise, the G542X and N1303K mutations
were estimated to be N34000 years old [14]. In another
paper, Cashman et al. [16] calculated 170 generations
(N3200 years) for the G551D mutation.
Recently, Génin et al. [17] presented a likelihood-based
method to estimate the age of themost recent common ancestor
of raremutations carriers. By simulations, they showed that the
method provides reliable age estimates with a 95% confidence
interval, even with small sample sizes (n≥5). They used this
method to estimate the age of the IVS14+1GNA mutation
within the AAAS gene involved in Triple-A syndrome, carried
by nine patients fromnorthAfrican origin. They calculated that
the most recent common ancestor should have lived ∼1000–
1175 years (39–47 generations) ago. In this paper, we made
use of this method to estimate the age ofCFTRmutant carriers
in the population from Brittany.
2. Materials and methods
2.1. CF patients
Unrelated CF patients (and relatives when available) from
Brittany carrying at least one of the following mutations
W846X2, 1078delT, G551D and ΔF508-I1027T were
selected for the study, accounting for 13, 31, 32 and 10
families, respectively (Table 1). It should be noted that the
notations ΔF508, G551D, W846X2 and I1027T should
no longer be used and be replaced respectively by p.F508del,
p.G551D, p.W846X and p.I1027T at the protein level; and
c.1521_1523delCTT, c.1652GNA, c.2538GNA, c.3080TNC,
as well as c.946delT for the 1078delT mutation at the
DNA level according to the recommended nomenclature
(http://www.hgvs.org/mutnomen/).DNA samples were obtained from the Laboratoire de
Génétique Moléculaire, CHU Morvan-EFS Bretagne (Brest,
France). DNA from blood spots was extracted using
GENERATION® Capture Card kit from Gentra (purchased
from Coger, Paris, France) according to the manufacturer's
instructions.
2.2. Microsatellite analysis using universal fluorescent
labeling (UFL)
Microsatellites were selected by a software freely
available at the following URL: http://zeon.well.ox.ac.uk/
git-bin/microsatellite.cgi. Contiguous sequences round the
CFTR gene (7q31) were successively screened for micro-
satellite regions. Ten unreported sequences containing either
di- or tetra-nucleotide motifs were selected for the study, one
of which is located within CFTR intron 1 (Table 2) (Base
pair positions may be provided by the corresponding author
upon request). These sequences were amplified by multiplex
PCRs using Universal Fluorescent Labeling (UFL), which
principle has been previously well described [18,19]. This
system allows the study of multiple labeled amplicons which
sizes are theoretically equivalent in a single tube by using
different fluorescent dyes. Two different 20-nucleotide (nt),
universal forward primers, U-FAM and U-HEX [20], were
5′-tagged with 6-carboxyfluorescein (6-FAM) and hexa-
chlorofluorescein (HEX), respectively (Table 2). These
primers do not have any sequence homology with any
regions of the human genome. Primers amplifying the
regions of interest were designed with PrimerQuestSM from
Table 2
Primers for amplification of markers
Amplicon Repeated motif Distance from CFTR a Primer b Primer sequence c (5′→3′) Size range (bp)
U-FAM GTCGTAGTCGACGACCGTTA
U-HEX GACTTCGGATAGCTAGTCGT
M01 ca −5.0 M01F-F GTCGTAGTCGACGACCGTTAAGCAGCTATTATGGAATTGC 200–220
M01R CAACATATGCAAGGTGCCTA
M02 ca −2.7 M02F-H GACTTCGGATAGCTAGTCGTATGGCTTTTTGCATACTAAATGCTT 110–140
M02R CATGGTTCTGGCTGCTGA
M03 ct −2.1 M03F-H GACTTCGGATAGCTAGTCGTATGTTTGAGAGCTCTTCCCTCCTG 190–210
M03R CTGCACCTTCTACATCTTTGTAGGC
M04 ctat −1.7 M04F-F GTCGTAGTCGACGACCGTTATGTGTCTGGCTTCCTTTATTCAAC 260–290
M04R GGCACAATTGCCTTGGAAACCTGA
M05 ca −1.1 M05F-H GACTTCGGATAGCTAGTCGTTTTCCAGAACACGGCATCTTCACG 290–310
M05R TGCTACCCAGGATTTGACAGGCTA
M09 gt ⁎ M09F-H GACTTCGGATAGCTAGTCGTTTGGAATTTTTGTCCTAAGAAATG 240–270
M09R GATCCCTAAGGCATACAGATTTT
M10 gt +0.7 M10F-H GACTTCGGATAGCTAGTCGTTGCAGTGAGGAGACACCAAAGTCT 220–240
M10R CCCACTTCAGACACCATACATACA
M11 ca +1.4 M11F-H GACTTCGGATAGCTAGTCGTACAGAGCCCTAAAGTACAGTCACA 300–330
M11R ACGGGCAAACCACAGGTCATCTAA
M12 agat +2.0 M12F-H GACTTCGGATAGCTAGTCGTTTGATGTGTACGTCACACTGCTGC 270–300
M12R TGCTTAAGCCAACTGGTATGTGGT
M13 ca +3.1 M13F-H GACTTCGGATAGCTAGTCGTGAGAGCTTCACACATCTCAGTGCT 230–250
M13R GCAAGGCTGCCTGCTTTGAATATG
a Physical distance (Mb) between the marker and the CFTR gene (− for centromeric, + for telomeric). ⁎ This microsatellite is localized within CFTR intron 1.
Mb: megabase.
b F or H at the end of the forward primer name indicates the specific primers with either U-FAM or U-HEX universal tail, respectively.
c Universal tails within the sequences are underlined.
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Forward primers were tagged at their 5′-end with either 20-nt
sequence for labeled specific amplifications. Three multiplex
PCRs were carried out to amplify the ten regions of interest
for each DNA sample. In a first series, amplicons M01, M04,
M05 and M13 were amplified together; M03, M09 and M11
were amplified in a second set, and M02, M10 and M12 in a
third series. Amplifications were carried out in a 10 μL
reaction volume with ∼20 ng genomic DNA, 2 mM Mg2+,
250 μM dNTPs each, 0.2 μM U-FAM, 0.2 μM U-HEX,
0.2 μM reverse primer, 4 nM forward specific primer (1/50th
reverse primer concentration) and 0.25 U AmpliTaq Gold®
(Applied Biosystems, France). Cycling conditions were
95 °C for 10 min, followed by 35 cycles of 95 °C for 1 min,
56 °C for 1 min, 72 °C for 1 min, with a final extension step
of 20 min at 72 °C in a GeneAmp PCR 9600 SystemTable 3
Estimation of the age of the CFTR mutations
Mutation Number of chromosomes Age in generations [95% CI] Age in y
W846X2 13 25 [15;41] 625 [37
1078delT 32 40 [30;53] 1000 [75
G551D 33 48 [36;62] 1200 [90
ΔF508 45 115 [91;148] 2875 [22
I1027T 10 24 [13;44] 600 [32
Mut and Pol respectively indicate the relative position of the mutation and the po
a Assuming that one generation is 25 years.
b Each genotype corresponds to the size of the amplicon as indicated by Fragm(PerkinElmer, France). One microlitre reaction product was
mixed with 14 μL deionized formamide and 0.25 μL
MegaBACE™ ET400-R Size Standard (GE Healthcare,
Orsay, France) and denatured 5 min at 95 °C prior to
genotyping. The ten microsatellites were then genotyped
with the MegaBACE 1000 (GE Healthcare) according to the
manufacturer's instructions, using its multicolor detection
capability. Data were analyzed with Fragment Profiler v1.2
(GE Healthcare). Homozygous were sequenced to confirm
the identity of the amplified regions (data not shown).
2.3. Haplotype reconstruction
Haplotypes at the 10 microsatellites loci were recon-
structed in the sample of cases using PHASE Version 2 with
the possibility of recombination between markers [21,22].ears a [95% CI] Assumed ancestral haplotype b
5;1025] 201–123–195–275–306–250–Mut–226–318–277–243
0;1325] 199–123–201–279–310–250–Mut–228–308–281–243
0;1550] 207–113–197–275–302–264–Mut–224–322–293–239
75;3700] 209–117–201–283–308–256–Mut–224–308–281–243
5;1100] 209–123–203–271–308–256–Pol–228–308–289–243
lymorphism within each haplotype of interest. CI: confidence interval.
ent Profiler v1.2 (GE Healthcare).
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allowed the reconstruction of either the entire or a part of
the patient haplotypes, the information was passed to
PHASE Version 2.
2.4. Estimation of mutation ages
The age of the most recent common ancestor of the
patients carrying the different CF mutations was estimated
using the estiage program [17]. The method implemented in
this program is a likelihood-based method that uses a
multilocus marker data information on patients. It is assumed
that all affected individuals in the sample descended from a
common ancestor, who introduced the mutation n genera-
tions (ngen) ago. An estimate of ngen is obtained from the size
of the haplotype shared by the individuals on both sides of
the disease locus by finding the most-likely positions of
recombinations on the ancestral haplotype in the different
patients. Allele frequencies of the markers and mutation
rates are taken into account to allow for the possibility that
recombinations occurred in previous intervals but with
haplotypes sharing the same alleles as the ancestral
haplotype, or to let haplotype diversity be due to mutations
rather than recombinations.
When haplotypes are not known with certainty but
reconstructed, the posterior probabilities of the different
possible haplotypes for an individual are used as weights in
the method. Marker allele frequencies in the population were
obtained by allele counting on the different non-CF-mutated
chromosomes of relatives and, for each CF mutation, it was
assumed that the ancestral haplotype is the most frequent
haplotype found on chromosomes carrying the mutation. A
mutation rate of 10−4 per individual per generation and a
stepwise mutation model were assumed at the ten micro-
satellite markers [17].
3. Results
3.1. CFTR mutations
All available DNAs from CF patients carrying mutations
W846X2, 1078delT or G551D, and relatives had been
previously genotyped in the laboratory (Table 1). A total of
13 chromosomes were studied for the W846X2 mutation, 32
for 1078delT and 33 for G551D (one homozygous patient for
the two latter mutations). As expected, the ΔF508 mutation
is the most associated in trans with the three other mutations
of interest (45/75, 60.0% of the total associated mutations):
6/13 (46.2%), 21/31 (67.7%) and 18/32 (56.3%) with
W846X2, 1078delT and G551D, respectively. These 45
ΔF508 chromosomes were used for dating the mutation.
Among these chromosomes, 2/45 (4.4%) carry the I1027T
polymorphism in CFTR exon 17a. An additional set of
ΔF508 chromosomes was screened for the polymorphism,
accounting for a total of ten chromosomes carrying the
ΔF508-I1027T haplotype. In this latter cohort, the ΔF508and G551D alleles are respectively carried in trans by eight
(8/10) and two (2/10) patients.
Three other mutations were found twice: 621+1GNT
(trans-associated with W846X2 and G551D), 2789+5GNA
(with W846X2 and G551D) and 4005+1GNA (with
1078delT). The other associated mutations were observed
only once.
3.2. Genotyping, haplotyping and estimations of mutation
ages
Among the ten microsatellite markers, five are located on
the centromeric side, four on the telomeric side and one
within the gene (CFTR intron 1). All regions were amplified
by universal fluorescence labeling (UFL), multiplex PCRs.
Data were collected for each individual and haplotypes were
constructed by using PHASE v2 (Supplemental data).
For each haplotype, the frequency probability was
calculated and the age of the most recent common ancestor
was estimated for each mutation with a 95% confidence
interval (Table 3). As expected, the ΔF508 most recent
common ancestor is older than those carrying the other
mutations (∼3000 years). The G551D and 1078delT
mutations are assumed to be appeared in Brittany at the
end of the First Millenium while W846X2 and I1027T are
very likely the most recent (∼600 years).
4. Discussion
We used a simple likelihood-based method to estimate the
age of the most recent common ancestors carrying CFTR
mutations in a specific population. This method has proven
useful for estimating the age of rare mutations such as the
IVS14+1GNA mutation involved in Triple-A syndrome in
patients from north African origin [17] by studying the
frequency of polymorphic markers surrounding the gene of
interest (i.e., ten microsatellites in our study). Although
relatively rare, W846X2, 1078delT, G551D and I1027T are
found at higher frequency in the population from Brittany
than in the other French regions. The approach that is used is,
therefore, very appropriate for estimating the age of these
mutations. As chromosomes carrying the ΔF508 mutation
were available, we also applied the system to this mutation.
The W846X2 mutation as well as the I1027T polymor-
phism were estimated to be ∼600 years old, while 1078delT
was found to be older (∼1000 years old) in Brittany. To our
experience, the first two variants have been almost
exclusively found in CF patients originated from Brittany.
Although observed in other countries, 1078delT-mutant
carriers constitute single cases in their population and the
frequency of the mutation is only significant in the region of
interest. It remains however unclear whether the three
variants appeared in the area, or if they were introduced by
specific carriers, suggesting founder effects [23]. Assuming
that these three mutations were born in the region, our
estimations give the respective ages of the mutations
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limited at that time, especially in western Brittany, another
scenario can be suggested. Plague epidemies, which
occurred in the last millenium in Europe, may have
dramatically reduced the population, then suggesting a
bottleneck from which the mutations have been confined in
the area. It would, therefore, explain their specific localiza-
tion and our estimates here would calculate the period of
these bottlenecks rather than the age of the mutations.
The G551D mutation is commonly found in Caucasian
populations from Scotland [24], Wales [25], Ireland [12,26],
Australia and the USA (www.genet.sickkids.on.ca/cftr/). The
most recent common ancestor for this mutation, also known
as the « Celtic mutation », is ∼1200 years old in Brittany. It
has been assumed that it was very likely introduced by
people coming from Great Britain to western France in a
period of migrations that is known to have occurred in the
second part of the First Millenium (6th–7th century). The
estimation of its age thus correlates with this migration.
Our results also indicate that theΔF508mutationwas likely
introduced in Brittany ∼3000 years ago (« Bronze Age » and
« Iron Age »), presumably by Indo-European Celts migrating
to western Europe and British Isles at that time. Multiple
haplotypes associated with the mutation, which differ from the
assumed ancestral haplotype, have been observed suggesting,
as expected, that multiple waves of introduction of this
mutation have occurred since. This latter estimate is, therefore,
questionable because the method is more dedicated to rare
mutations while ΔF508 is very common.
In summary, we estimated the ages of the most recent com-
mon ancestors in the population fromBrittany carrying different
mutations within the CFTR gene by genotyping a series of
polymorphic markers surrounding the gene. These estimations,
in a specific population such as people from Brittany, are of
particular interest since they give historical perspectives in the
field of understanding population migrations. This work ac-
tually illustrates what can be accomplished when combining
genetics and historical data, and this kind of strategy may be
useful to study population origins in several world areas.
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